Ibrance
Term · Oncology and biomedicine · MLC-T-ONC-004108
A drug used to treat women and men with certain types of hormone-receptor positive, HER2-negative breast cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Ibrance blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Also called palbociclib.
| Identifier | MLC-T-ONC-004108 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | palbociclib |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-004108",
"term": "Ibrance",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat women and men with certain types of hormone-receptor positive, HER2-negative breast cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Ibrance blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Also called palbociclib.",
"synonyms": [
"palbociclib"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/ibrance/"
}
Record 8,892 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.